COVID-19 (Coronavirus) Update: Vaccine Updates | COVID-19 Information | Visitor Guidelines

A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (done) and Phase 2 (Dose Expansion of CPI- 0610 with and without Ruxolitinib in Patients with MF)

Protocol No
CONSTELLATION-0610-02
Principal Investigator
Laura Michaelis
Phase
I/II
Summary
This project is being done to evaluate the disease response to CPI-0610 alone or CPI- 0610 in combination with ruxolitinib in patients with Myelofibrosis.
Description
A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL